MAZE
NASDAQMaze Therapeutics Inc.
Price$23.67-0.56 (-2.33%)
01:30 PM07:45 PM
News · 26 weeks67+7%
2025-12-142026-06-07
Mix4290d
- Insider21(50%)
- SEC Filings13(31%)
- Other4(10%)
- Earnings2(5%)
- Analyst1(2%)
- Offering1(2%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Spiegelman Daniel K4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERSEC Form 4 filed by Director Scheller Richard H4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERSEC Form 4 filed by Director Lim Jonathan E4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERSEC Form 4 filed by Director Hoppenot Herve4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERSEC Form 4 filed by Director Homcy Charles J4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERSEC Form 4 filed by Director Andrews Nancy C4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- SECSEC Form 8-K filed by Maze Therapeutics Inc.8-K - Maze Therapeutics, Inc. (0001842295) (Filer)
- INSIDERChief Executive Officer Coloma Jason V sold $174,048 worth of shares (6,643 units at $26.20) as part of a pre-agreed trading plan (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERPresident, R&D & CMO Bernstein Harold sold $381,112 worth of shares (14,853 units at $25.66) as part of a pre-agreed trading plan and exercised 14,853 shares at a strike of $10.42 (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERCSBO Dandekar Atul exercised 7,500 shares at a strike of $10.42 and sold $197,554 worth of shares (7,500 units at $26.34) as part of a pre-agreed trading plan (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- SECSEC Form 144 filed by Maze Therapeutics Inc.144 - Maze Therapeutics, Inc. (0001842295) (Subject)
- INSIDERChief Executive Officer Coloma Jason V sold $847,048 worth of shares (32,564 units at $26.01) as part of a pre-agreed trading plan (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- PRMaze Therapeutics to Participate in Two Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will participate in two upcoming investor conferences: 2026 Jefferies Global Healthcare Conference in New York; presentation on Wednesday, June 3, 2026, at 3:45 p.m. ETGoldman Sachs 47th Annual Global Healthcare Conference 2026; presentation on Wednesday, June 10, 2026, at 8:40 a.m. ET Live webcasts of the events will be available in the Investors section of the Maze
- SECSEC Form 8-K filed by Maze Therapeutics Inc.8-K - Maze Therapeutics, Inc. (0001842295) (Filer)
- INSIDERChief Executive Officer Coloma Jason V sold $50,388 worth of shares (1,938 units at $26.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERPresident, R&D & CMO Bernstein Harold exercised 15,000 shares at a strike of $10.42 and sold $393,354 worth of shares (15,000 units at $26.22) as part of a pre-agreed trading plan (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- SECSEC Form 144 filed by Maze Therapeutics Inc.144 - Maze Therapeutics, Inc. (0001842295) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Maze Therapeutics Inc.SCHEDULE 13G/A - Maze Therapeutics, Inc. (0001842295) (Subject)
- SECSEC Form EFFECT filed by Maze Therapeutics Inc.EFFECT - Maze Therapeutics, Inc. (0001842295) (Filer)
- SECSEC Form 10-Q filed by Maze Therapeutics Inc.10-Q - Maze Therapeutics, Inc. (0001842295) (Filer)
- SECMaze Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Maze Therapeutics, Inc. (0001842295) (Filer)
- SECSEC Form POS AM filed by Maze Therapeutics Inc.POS AM - Maze Therapeutics, Inc. (0001842295) (Filer)
- PRMaze Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsPositive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late 2026 or early 2027 Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD on track to initiate in 2026 Strong balance sheet with $528 million in cash, cash equivalents and marketable securities; inclusive of net proceeds from the $150 million registered offering and $20 million MZE001 milestone payment in April 2026; cash runway expected to extend into 2029 SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage b
- INSIDERCSBO Dandekar Atul exercised 14,305 shares at a strike of $10.42, increasing direct ownership by 136% to 24,808 units (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
- INSIDERDirector Homcy Charles J gifted 7,422 shares, decreasing direct ownership by 19% to 31,113 units (SEC Form 4)4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
MAZE FAQ
6 questionsWhere does MAZE stock trade?
Maze Therapeutics Inc. (MAZE) is listed on NASDAQ.What sector and industry is MAZE in?
Maze Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Maze Therapeutics Inc. go public?
Maze Therapeutics Inc. (MAZE) completed its IPO in 2025.What are analysts saying about MAZE?
Maze Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from Truist: Buy on 2026-03-18. Recent price targets range from $1700.00 to $3400.00.What companies are similar to MAZE?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare MAZE side-by-side with any of them on Quantisnow.How can I track MAZE on Quantisnow?
Quantisnow aggregates Maze Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MAZE to receive live email and push alerts on every new disclosure.